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Δε   : Extinction coefficient 
6-APA   : 6-aminopenicillanic acid 
7-ACA   : 7-Aminocephalosporanic acid 
A. salmonicida  : Aliivibrio salmonicida 
asMBL   : Aliivibrio Salmonicida metallo-beta-lactamase 
AU   : Absorption Unit 
B. subtilis  : Bacillus subtilis 
BBL   : Standard numbering scheme for class B beta-lactamases 
BLAST   : Basic Local Alignment Search Tool 
BSA   : Bovine Serum Albumin 
CV   : Column Volume 
DHF   : Dihydrofolate 
DLS   : Dynamic Light Scattering 
DMSO   : Dimethyl sulfoxide 
DNA   : Deoxyribonucleic acid 
dNTP   : Deoxyribonucleotide 
DTT   : Dithiothreitol 
E. coli   : Escherichia coli 
EARSS   : European Antimicrobial Resistance Surveillance System 
EDTA   : Ethylenediaminetetraacetic acid 
EEA   : European Economic Area 
EFTA   : European Free Trade Association 
ESBL   : Extended-spectrum beta-lactamase 
EU   : European Union 
ExPASy   : Expert Protein Analysis System 
Hepes   : 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IPTG   : Isopropyl β-ᴅ-1-thiogalactopyranoside 
kcat   : Turnover number used in Michaelis-Menten kinetics 
Km   : Dissociation constant for enzyme-substrate (ES) complex used in Michaelis- 
  Menten kinetics 
LB   : Lysogeny Broth 
LD   : Loading Dye 
MBL   : Metallo-beta-lactamase 
Mes   : 2-(N-morpholino)ethanesulfonic acid 
MIC   : Minimum inhibitory concentration 
MTEN   : Buffer consisting of Tris, ethanolamine, Mes and NaCl 
MW   : Molecular Weight 
nt   : Nucleotide 
NOK   : Norwegian Kroner 
OD   : Optical density 
P. aeruginosa  : Pseudomonas aeruginosa 
PABA   : Para-aminobenzoic acid 
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PBP   : Penicillin Binding Protein 
PCR   : Polymerase Chain Reaction 
PDB   : Protein Data Bank 
pKa   : Acid dissociation constant 
ppMBL   : Photobacterium profundum 
RNA   : Ribonucleic acid 
SDS-PAGE  : Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SD   : Standard deviation 
SI   : Sub-inhibitory 
ssMBL   : Shewanella sediminis 
TAE   : Tris-acetate-EDTA 
TCEP   : Tris(2-carboxyethyl)phosphine 
THF   : Tetrahydrofolate 
Tris   : Tris(hydroxymethyl)aminoethane 
vfMBL   : Vibrio fischeri 





Beta-lactamases are enzymes that inactivate beta-lactam antibiotics by hydrolyzing the 
amide bond that exists in the beta-lactam ring, disrupting the ring structure and make the 
antibiotics nonfunctional against bacteria. Metallo-beta-lactamases (MBLs) are a group of 
beta-lactamases which needs metal ions bound to its active site in order to function and are 
an important factor in many bacteria in order to be resistant to antibiotics. Resistance to 
antibiotics is a serious health problem which increases with excessive use of antibiotics. This 
study is based on the purification and characterization of MBL from the psychrophilic 
organism Aliivibrio salmonicida which is the causative agent for the Hitra disease, or cold-
water vibrosis, in seawater-farmed Atlantic salmon (Salmo salar). Characterization of asMBL 
has revealed interesting properties in regards of temperature-, salt-, pH optimum and 
enzyme kinetics. asMBL properties have been compared to VIM-7, a MBL isolated from 
hospital which thrives in mesophilic conditions. Compared to VIM-7, asMBL proves to be 
adapted to the colder and saltier environment of the seawater. asMBL enzyme kinetics have 
also been compared to MBLs from human pathogenic bacteria and asMBL showed a general 
lower enzymatic efficiency in terms of lower kcat and higher Km at the same experimental 
conditions as the other MBLs. Nitrocefin, the substrate used for the characterization of 
asMBL, had its stability in temperature, pH and Tris investigated. From these investigations it 
seems plausible that nitrocefin is auto-hydrolyzed in a synergetic matter when present at 
high pH and in Tris buffer. An attempt to crystallize the protein and retrieve a structure was 
unsuccessful as it turns out that the protein seems to be aggregating at high concentrations. 
Keywords 
Marine environment adaption; salt tolerance; nitrocefin stability; enzyme characterization; 
purification; metallo-beta-lactamase; temperature stability; experimental parameters; enzyme 
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Aim of study 
First and foremost the goal of this study was to produce pure asMBL in high enough quantity 
to crystallize it and ultimately solve the structure of the protein.  
As asMBL originates from a marine organism living in colder and saltier condition compared 
to organisms inhabiting human environment, it was interesting to see how enzymes from 
these two environments would be different. To clarify these apparent differences, the aim 
was to characterize asMBL optimal conditions in terms of pH, temperature, salt and kinetic 
studies. As the study went on, an interest of how different experimental parameters affect 





Beta-lactamases – classification 
Metallo-beta-lactamases belongs to the protein family of beta-lactamases, a group of 
enzymes which breaks open the ring structure of beta-lactam antibiotic and deactivates it. 
There are approximately 900 sequences of beta lactamases which have been reported, and 
of these, about 80 sequences of metallo-beta-lactamases have been reported (1, 2). From 
figure 1 we can observe how the discovery of unique beta-lactamases has been throughout 
the years. 
 
Figure 1 The discovery of different beta-lactamases over the years. Figure retrieved from Bush et al (1). 
Beta-lactamases are being classified in two different ways; functional classification, which 
emphasizes on the substrates and inhibitors of the protein, and molecular classification, 
which is based on the amino acid sequence of the proteins. 
Functional classification 
All beta-lactamases are divided into three different functional groups by Bush et al (1). 
Group 1 beta-lactamases is termed cephalosporinases. These beta-lactamases prefers 
cephalosporin substrates and is not inhibited by EDTA or clavulanic acid and/or tazobactam. 
Representatives for this group are ACT-1 (3), FOX-5 (4) and AmpC ADC-33 (5). 
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Group 2 is by far the largest group of beta-lactamases, consisting of serine beta-lactamases. 
This group of beta-lactamases consists of many subgroups (2a, 2b, 2be, 2br…) and their 
preferred substrates range from penicillins, cephalosporins, monobactams, carbenicillin, 
cefepime, cloxacillin and carbapenems. These enzymes will not be inhibited by EDTA, but 
most of them are inhibited by clavulanic acid and/or tazobactam. Examples of group 2 
enzymes are TEM-135 (6), OXA-1 (7), and cepA (8). 
Group 3 consists of MBLs which is the group that the beta-lactamase from A. salmonicida, 
asMBL, belongs to. This group’s generally preferred substrate is carbapenems. MBLs will not 
be inhibited by clavulanic acid and/or tazobactam, but will be inhibited by EDTA, because of 
the chelating properties of EDTA. 
The group 3 beta-lactamases is divided into two subgroups, 3a and 3b, where 3a consists of 
MBLs having a broad range of different substrate which it can hydrolyze, while 3b MBLs 
mainly hydrolyze carbapenems. Enzymes belonging to the group 3a are the likes of IMP-19 
(9), IND-5 (10) and VIM-19 (11). Subgroup 3b is smaller than 3a, and consists of for instance 
CphA from Aermonas hydrophilia (12) and Sfh-1 (13). 
Molecular classification 
Ambler (14) proposed a molecular classification of beta-lactamases based on sequence 
similarity in 1980. This classification divides the beta-lactamases into 4 groups; A, B, C and D. 
This classification has similarities with the functional classification, as the molecular groups A 
and D are the same as the functional group 2 (serine beta-lactamases), the molecular group 
B corresponds to the functional group 3 (metallo-beta-lactamases) and the molecular group 
C corresponds to the functional group 1 (cephalosporinases). 
However, when in the functional classification, the metallo-beta-lactamases are divided into 
2 subgroups, in the molecular classification the metallo-beta-lactamases are divided into 3 
subgroups; B1, B2 and B3. Even though B1 and B3 belong to two different subgroups and 
have weak sequence similarity, they have a high degree of structural similarity (15). Both B1- 
and B3-enzymes need two zincs bound for maximum activity, while B2-enzymes will be 





Figure 2 The structure of IMP-1, a similar MBL belonging to the molecular class B1. The enzyme is in complex with a 
mercaptocarboxylate inhibitor. The inhibitor and the two zinc ions indicate the whereabouts of the active site of MBL. 
This figure is retrieved from RCSB of PDB ID: 1DD6 (17). 
Metallo-beta-lactamases have fairly similar structures which consists of an αββα structure 
composed of two central beta-sheets and 5 solvent-exposed alfa-helices (see figure 2) (18). 
From observations of active site orientation of all known structures it is concurrent that the 
active site of MBLs is to be residing in the external edge of the ββ-sandwich. It has been 
suggested that he structure of metallo-beta-lactamases arose from a duplication of a gene 
(19), since the N-terminal and C-terminal parts of the molecule can be superposed by a 180 
rotation around a central axis. The N-terminal of B1 metallo-beta-lactamases includes a loop 
(residues 61-65) that is not present in subclasses B2 or B3 (18), and is important for the 
activity of the enzyme (20). 
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The active site consists of two zinc-binding regions which are conserved among the class B1, 
B2 and B3 metallo-beta-lactamases (table 1). 
Table 1 Numbering of the ligands binding Zn2+ ions in the different metallo-beta-lactamases molecular groups based on 
the work of Garau et al 2004. BBL = Standard numbering scheme for class B beta-lactamases. 
Functional 
group 
Zn1 ligand Zn2 ligand 
Consensus 
BBL B1 
His116 His118 His196 Asp120 Cys221 His263 
Consensus 
BBL B2 
Asn116 His118 His196 Asp120 Cys221 His263 
Consensus 
BBL B3 
His/Gln116 His118 His196 Asp120 His121 His263 
 
Most MBLs are functional active as dizinc compounds, but enzymes belonging to the B2 
subgroup are active as a monozinc compound and will be inhibited if two zinc ions are bound 
to it (21). The characteristics and importance of binding of zinc to the two zinc binding 
regions vary among the different MBLs, where the dizinc and monozinc component are 
discussed (22-24). 
In B1 enzymes the binding of zinc is believed to be similar to how it is in BcII from Bacillus 
Cereus (25). The Zn1 metal is tetracoordinated by the three histidines (His116, His118 and 
His196) and a water molecule (figure 3). The Zn2 metal is pentacoordinated by His263, 
Asp120, Cys221 and a water molecule which is bridging the two metals. The fifth ligand to 
the Zn2 metal is a carbonate (25) or a water molecule (26). The water molecule bridging the 




Figure 3 Active site of dizinc BcII, illustrating electrostatic interactions between zinc ions and MBL. The zinc ions are the 
big grey spheres while the small, red spheres are water molecules. The hydroxide bridging the two zinc ions is available 
at a pKa value of less than 5.25 (27). Figure is retrieved from Baderau et al (28). 
The mechanism on how MBL performs its hydrolysis has not been agreed upon. A suggestion 
on how a dizinc MBL performs its catalytic activity proposed by Wang et al follows (27) 
(figure 4): 
The reaction’s first step is that the nitrogen bound on the substrate interacts with Zn2 and 
displaces the water previously bound. Zn1 together with Asn-193 acts like an oxyanion hole 
for the carbonyl group of the beta-lactam compound. The hydroxide bound to Zn1 acts as a 
nucleophile and disrupts the C-N bond. Zn2 ion stabilizes the intermediate by electrostatic 
interactions on the charged nitrogen. The intermediate is being transformed to product by 
protonation of the negatively charged nitrogen and the enzyme is regenerated by ligand 




Figure 4 Mechanism of dizinc MBL as in the case of BcII from Bacteroides fragilis. Figure retrieved from Wang et al (27). 
Aliivibrio salmonicida 
The MBL studied in this report is originating from Aliivibrio salmonicida which is a gram-
negative, motile and rod-shaped bacterium, previously known as Vibrio salmonicida (29). It is 
found in marine environment and is often associated with fish; some species have been 
regarded as pathogens of marine animals as for instance the causative agent of Hitra disease 
or cold-water vibrosis. This is a condition that appeared in the late 1970s in Norwegian fish 
farms and has most exclusively been recognized in farmed Atlantic salmon (Salmo salar L.), 
but this serious problem was solved through vaccination (30). 
Enzyme activity, cold adaption and salinity 
Enzyme activity is influenced by many factors. Salt concentration, temperature, pH and 
substrate saturation are some of the most important parameters and these change 
according to the type of protein and what environment it belongs to. In the case of MBL 
from A. salmonicida, the environment which surrounds this protein is seawater because this 
protein resides in the periplasm of the cell or is secreted further to the extracellular 
environment. It is reasonable to think that such secreted enzymes are very much affected by 
the surroundings of the bacteria and have through evolution adapted to function optimally 
here. 
Coastal seawater has a salinity of about 3.5% and contains about 470 mM Na+ and 540 mM 
Cl- (31). Another important component in seawater related to MBL is the content of Zn2+, 
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which is 0,005 ppm or 76 nM (31). The pH in seawater is around 8.0 to 8.2 (32), but could 
vary according to special local conditions. Based on numbers presented by Institute of 
Marine Research from their hydrographic station in Eggum, the coastal average temperature 
in the Norwegian Sea can be estimated to be between 5 to 6 0C in January and between 10 
and 110C in July (33). 
Tolerance to salt and low temperature is features of the exposed marine proteins, which 
show how they are adapted to their environment (34). Halophilic enzymes, enzymes 
adapted to high concentrations of salt are, for instance characterized by an abundance of 
acidic amino acids which is believed to increase the proteins aqueous solubility and protect it 
from the salting out effect (35). Another feature of most halophilic proteins is that they are 
inactivated by salt concentrations of less than 2 M NaCl or KCl (36, 37). Temperature 
adaption is seen as a higher flexibility of structure seen in cold adapted enzymes. Higher 
flexibility leads to an unfolding of the protein at lower temperatures and higher specific 
activity at low temperatures compared to mesophilic enzymes. In terms of enzyme kinetics, 
cold adapted enzymes have a high kcat and high Km (36). 
Salt influences the protein by neutralizing charges on the protein surface, and as a 
consequence of this, stabilize the protein (38). The stabilization of the protein is also a result 
of a gain in hydrophobic effect, which strengthens the folded state of the protein (38). Even 
though a decrease of positive electric interactions also occurs when charges are neutralized, 
this seems not to affect the positive net effect the salt has on the stability of the protein. 
Michaelis-Menten kinetics 
In order to study enzyme kinetics in regards of asMBL’s hydrolysis of beta-lactam substrates, 
the Michaelis-Menten model is used to describe the enzymatic reactions.  The model relates 







Vmax and Km are kinetic constants, in which Vmax is defined as the maximum reaction rate of 
the enzyme and Km is defined as the substrate concentration in which the enzyme has a 
reaction rate of half Vmax. Km indicates how efficiently an enzyme selects its substrate and 
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converts it to product. Vmax is reached as the substrate concentration reaches infinity, which 
means that the reaction rate (V0) asymptotically reaches Vmax (figure 5). This can be easily 
visualized when letting [S] go to infinity, the value of Km could be neglected, as it is a 
constant. [S] above and below the fraction line cancel each other out, which leaves us with 
V0=Vmax. This relation between [S] and reaction rate tells us about how the efficiency of the 
enzyme increases as the enzyme is saturated with substrate.  
 
Figure 5 Vmax and Km is illustrated according to the Michalis-Menten model; the numbers on the x-axis and y-axis are 
examples of substrate concentrations and reaction rates. The figure is retrieved from Wikipedia (39). 
The basic model (figure 6) which the Michaelis-Menten kinetics is based on is explained as; 
the enzyme (E) binds reversibly to substrate (S) to form a complex (ES) which eventually 
converts into product P and regeneration of the enzyme. Two assumptions are made in 
order to convert this model into an analysis of Km and Vmax; the concentration of ES is steady 
during the time interval of the kinetic reaction and the formation of ES from E+P is 
negligible, because the concentrations of product is low at the start of the reaction. 
 
Figure 6 Basic model for enzyme kinetics 
k1, k-1 and k2 are rate constants that respectively tell the rate of complex (ES) formation, the 
reverse formation of substrate from complex and product formation.  For this type of simple 
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reaction kcat=k2, and can be termed as the turnover number as it indicates how many 
number of cycles that each active site undergoes per unit time. Kcat is related to Vmax and 





When analyzing the result of Michaelis-Menten kinetics an indication for a better performing 
enzyme is raised kcat and decreased Km. In order to estimate the enzyme’s overall 
performance kcat/Km, in which a raised value is positive indicator for the enzyme’s overall 
kinetic capability. 
Antibiotics 
A definition of antibiotics as suggested by Waksman (40), is as follows; An antibiotic is a 
chemical substance which has an antagonistic effect on an microbial environment. 
Antibiotics are often divided into two groups depending on their impact on the microbial 
target; i) bacteriostatic antibiotics – which halts bacterial growth and ii) bactericidal 
antibiotics – which kills the bacteria. The efficacy of antibiotics is often measured as MIC 
(minimal inhibitory concentration), which is the lowest concentration of antibiotics which 
inhibits the growth of a microorganism after overnight incubation. 
Antibiotics are being classified according to three main properties; i) The target on the 
bacteria cell for its antibacterial effect (figure 7) ii) The specificity of the antibiotics 
(spectrum) iii) The chemical structure of the antibiotic.  
A broad spectrum antibiotic works against many different bacteria, which makes this 
antibiotic precious considering resistance to antibiotics. Therefore the broad spectrum 
antibiotic is not administered as a first line of medication against bacterial infection. A 
narrow spectrum antibiotic is rather given as a first-line treatment, while the broad 




Figure 7 Different antibiotics and their antibiotic function. Retrieved from Wikipedia (41). 
As seen from figure 7, there are a lot of different types of antibiotics. Some of the most used 
antibiotics are the beta-lactams, macrolides and quinolones. 
Quinolones 
Quinolones are recognized by their heterobicyclic aromatic compound which often has a 
fluoride substitute (see figure 8), which makes it a fluoroquinolone. Quinolones work by 
blocking DNA replication leading to cell death, by forming complexes with DNA and either 
DNA gyrase or Topoisomerase IV (42). Compounds have, in addition to their antimicrobial 




Figure 8 The backbone of quinolones. 
Macrolides 
Macrolides are a structurally diverse group of antibiotics which are recognizable by their 
macrocyclic lactam ring (figure 9).The most important macrolide antibiotics are 14, 15 and 
16 membered ring compounds (44). The mechanism for the macrolides’ antibacterial effect 
is by inhibiting the protein synthesis by binding to the bacterial 50S ribosome subunit. 
Macrolides are used in the treatment of upper and lower respiratory tract infections caused 
by bacteria (45) and have also been seen as potential anti-inflammatory medication (46). 
 
Figure 9 Erythromycin, an example of a macrolide. The macrolide ring is the 14-membered ring at the upper-left corner. 
Beta-lactams 
Beta-lactam antibiotics are a large group of antibiotics known by their beta-lactam ring (see 
figure 10). These antibiotics target the cell wall biosynthesis pathway which causes an 
inhibition of the bacterial growth. This is done by inactivating PBP (penicillin binding 
protein), which causes irregularities in the peptidoglycan structure. Peptidoglycan is an 
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important structure in the bacterial cell wall, and irregularities in this component in the cell 
wall could lead to a hampering of its reproduction and eventually lead to cell death (47). 
 
Figure 10 The beta-lactam ring. 
Penicillin 
Penicillin is the best known beta-lactam antibiotic and it was discovered by Alexander 
Fleming in 1928 (48), which eventually lead to the Nobel prize in physiology/medicine in 
1945 for Alexander Fleming, Ernst Boris Chain and Howard Walter Florey because of 
penicillin’s discovery and its use in infectious diseases (49). The basic structure of penicillins 
consists of a thiazolidine ring (A) connected to a beta-lactam ring (B) (see figure 11). A side 
chain (R) is attached to the basic structure through a peptide bond, and this side chain 
displays the specific effect of the individual penicillin. When introducing a penicillin nucleus, 
6-aminopenicillanic acid (6-APA), examples of many penicillins we know today emerged, like 
methicillin, ampicillin and cloxacillin (50, 51).  
 
Figure 11 The backbone structure of penicillin, 6-APA. A= thiazolidine ring, B= beta-lactam ring. 
Cephems; cephalosporins and cephamycins 
Cephems is a subgroup of antibiotics which includes cephamycins and the more explored 
cephalosporins. Cephamycins are very much alike cephalosporins and are sometimes being 
termed as cephalosporins too. When synthesizing cephamycins, these compounds were 
believed to be more resilient towards beta-lactamase than their similar compounds 
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cephalosporins (52). An example of a cephamycin is cefoxitin (53, 54). The exploration of 
cephalosporins initiated when 7-ACA (7-Amino-Cephalosporanic Acid) (figure 12) was 
synthetized (50, 55), which is a cephalosporin scaffold in the same way as 6-APA is the 
scaffold when synthesizing different penicillins. Cephalosporins are usually classified into 
four different generations based on their antimicrobial activity, and for each generation its 
spectrum is more concentrated towards gram negative bacteria and resistance to beta-
lactamases (56). Examples of cephalosporins are; Cefuroxime (second generation) (57) 
Ceftadizime (third generation) (58), and Cefepime (59, 60). 
 
Figure 12 The backbone of cephalosporins, 7-ACA (61). 
Carbapenems 
This branch of beta-lactams was explored when thiamycine was synthetized, and this 
antibacterial showed good effect towards a broad spectrum of bacteria (62). But thiamycine 
was an unstable compound and therefore the synthesis of the more stable compound 
imipeneme (MK0787) was initiated and showed promising antibacterial activities (63). This 
initiated the exploration of the beta-lactam antibiotics group of carbapenems. An interesting 
feature of carbapenems is their trans configuration of their side chain (see figure 13), 
penicillins and cephalosporins have cis configuration of their side chain. This is believed to be 
the reason for their resistance against beta-lactamase activity (64). Examples of other 




Figure 13 The left structure illustrates a trans conformation which is typical for most beta-lactams, and the right structure 
illustrates a cis conformation which is typical for carbapenems. Figure based on the work of Birnbaum et al (64). 
Monobactams 
As the name implies they have a single beta-lactam ring structure (figure 14). The 
compounds of monobactams found in nature have no special antibacterial activity, but 
derivatives which are based on these natural monobactams have shown antibiotic activity 
(67). Aztreonam is the only clinically available monobactam, a compound with good activity 
against gram negative bacteria, but no activity against gram positive or anaerobic bacteria 
(68).  
 
Figure 14 Structure of Aztreonam. 
Nitrocefin 
Nitrocefin is a chromogenic compound which is used to detect the activity of lactamases 
(69). This substrate belongs to the cephalosporin group, a group which normally has 
absorption of substrate and product in the ultraviolet spectrum. Nitrocefin separates itself 
from the usual cephalosporins, as measuring the absorption of substrate and product is 
done by using wavelengths of visible light. This is thought to be a consequence of an 
unusually highly conjugation with the substituent at the third position at the β-lactam ring 
and the double bond in the dihydrothiazine ring (A) (se figure 15) (69). This unusual structure 
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is also a possible explanation for its reactivity, which has revealed this substrate’s usefulness 
as a reporter substance (70). 
 
Figure 15 Structure of nitrocefin A=dihydrothiazine ring 
Nitrocefin is often being used as a substrate for MBL. Fields of application are for instance 
using it as a detector of extended-spectrum beta-lactamases (ESBL) (71, 72), detecting the 
presence of beta-lactamase activity in bacteria (73-75) and also in kinetic analysis (76-78). 
Why beta-lactamases? - Where do beta-lactamases come from? 
Antibiotic resistance is by many thought of as a mechanism driven forward by man’s 
thoughtless use of antibiotics. The human behavior which causes and enhances the 
antibiotic resistance in bacteria is (79); i) overuse of antibiotics in medical relations. ii) The 
change of demographic parameters - the modern lifestyle of humans implicates a lot of 
traveling which causes spreading of antibiotic resistance. iii) The increased 
commercialization and effectiveness pressurizes food producers into a liberal use of 
antibiotics in the chase for a larger profit. 
The mechanism for transfer of antibacterial resistance In bacteria lies in plasmids which 
could be horizontally transferred between the different bacteria (79). Production of beta-
lactamases, and especially the production of Extended-spectrum beta-lactamases (ESBLs), in 
bacteria is seen as a serious threat to people’s health as beta-lactam antibiotics are 
frequently used as a treatment for pathogen bacterial infections. And metallo-beta-
lactamases have been seen as a foreseeable threat, since these proteins often provide a 
broad spectrum of resistance against different types of antibiotics. 
But where does the production of beta-lactamases originate from? First and foremost it is 
natural to think that the beta-lactamases was originally used in the fighting for the natural 
habitat amongst bacteria. Hypothetically, beta-lactamase production can be seen as a 
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response to a different organism’s capability to produce antibiotic. The production of toxins, 
or antibiotic, and the production of beta-lactamases could be seen as a part of a competitive 
evolution (80). 
In Alaskan environment where no human antibiotic pressure has been applied, a diverse set 
of lactamases have been found and also other substrates than the beta-lactam ring has been 
suggested for the beta-lactamases (81). In addition to the research in Alaskan environment, 
there have also been found many different species of Entero bacteria with a broad spectrum 
of resistance in freshwater with no connection to human activities (82). This indicates that 
human antibiotic overuse is perhaps not the only reason for multi antibiotic resistance found 
in bacteria. The reason for finding these “anomalies” is not very well known. 
But a possible hypothesis for finding resistance to antibiotics in natural bacterial colonies 
could be that the resistance functions as a regulator of quorum sensing (83). It is suggested 
that antibiotics are used to communicate between bacteria, which could mean that, for 
instance, beta-lactamase’s role is to adjust this quorum sensing signals. 
Quorum sensing is a way for bacteria to make a response when reaching some sort of a 
threshold, for instance a certain size of a bacteria colony. The response could be to make a 
biofilm, as seen in P. aeruginosa colonies (84). Other examples of quorum sensing are found 
in Vibrio fischeri giving a response of bioluminescence (85), Escherichia coli regulating its 
virulence factors (86), Acinetobacter baumannii  in regards of biofilm production (87) and 
Aeromonas hydrophilia by affecting its virulence capabilities (88). 
In the natural environment it is likely that the production of antibiotics is at the level of sub 
inhibitory (SI) concentrations, and microorganisms have been shown to respond to 
antibiotics in a certain way called hormesis (89). Hormesis is defined as a dose-response 
relationship where a low concentration gives stimulating processes until higher doses give 
toxic effects (see figure 16), which is thought to be a way for an organism to allocate its 
resources for optimal use (90). For instance, it is suggested that SI concentration of 
imipenem induce production of alginate, which compromises the effect of this antibiotic 
treatment (91), and SI concentrations of aminoglycoside induce biofilm formation in P. 
aeruginosa and Escherichia coli (92). Biofilm formation has the ability to protect bacteria 
from antibiotics (93). Sub inhibitory inflicts other responses in bacteria; induction of heat 
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shock genes and increased synthesis activity of purine nucleotide in Streptococcus 
pneumoniae (94), induction of a general stress response in Bacillus subtilis (95) and 
expression of genes involved in osmotic stress in Escherichia coli (96). 
 
Figure 16 An illustration of how hormesis could work in regards of antibiotic. Low doses of antibiotics will not affect the 
bacteria, but could in a certain range enhance the number of transcripts modulated. Higher doses of antibiotics disrupt 
cell multiplication and will not enhance the number of transcripts modulated. MIC = Minimum inhibitory concentration. 
Retrieved from Davies et al (89). 
Antimicrobial resistance impact on society 
Antibiotic resistance, including resistance to multiple antibiotics, is seen as a serious threat 
to human health. And judging from the report by the European Centre for Disease 
Prevention and Control (97), it seems like the resistance is increasing. For instance, it has 
been observed that Escherichia coli showed an increase of resistance to all antibiotic classes 
all across Europe (figure 17). E. coli is the most common Gram-negative bacteria which is 
responsible for urinary tract infections and bacteraemia (bacteria in the bloodstream) (97). 
Other resistant human pathogens are showing increasing resistance as well (97); i) Klebsiella 
pneumoniae show high levels of resistance to third-generation cephalosporins, 
fluoroquinolons and aminoglycosides. ii) Pseudomonas aeruginosa obtain resistance readily 
during antibiotic treatment and resistance to the five antimicrobial antibiotics recorded by 
EARSS was common (6%). iii) Enterococcus faecalis shows a high-level aminoglycoside 
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resistance and among most of the European countries aminoglycoside-resistant isolates 
varied from 25% and 50%. The increase of these resistances decreases the number of 
options for treating infections caused by bacteria. 
 
Figure 17  The increase of resistance to fluoroquinolons in E. coli from cerebrospinal fluid isolates in EU and EEA/EFTA 
countries from 2003 and 2008. Retrieved from EARSS (97). 
In Norway the defined daily dosage of antibiotics for systemic usage per 1000 inhabitants 
per day was 19.59 in 2010, which is an increase of 3% from 2009 (98). Defined daily dosage is 
an average maintenance dose per day for a drug (99). Norwegians used 450 million NOK on 
antibacterial medication and about a quarter of the Norwegian population picked up a 
prescription on antibacterial drugs in 2010 (98). 
In fish farms the organisms with antibiotic resistance are favored when antibiotics are 
introduced to the environment. For instance a study by Petersen et al showed that where 
integrated fish farming was performed an increase of antibiotic resistance bacteria was 
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observed (100). Integrated fish farming is a practice in which animal manure is introduced to 
fish farms to support growth of photosynthetic organisms. The animal manure originates 
from livestock which often were given antibiotics. 
Fish farming is an important industry in Norway - 840,343 tons of fish were produced in 2008 
and 742,976 tons of these were Atlantic salmon (Data provided by the Norwegian 
Directorate of fisheries) (101). The usage of antibiotics in fish farming is a way to ensure that 
as many farmed animals as possible can be healthy until they are slaughtered. In 1987 48 
tons of antibiotics were used. From 1987 to 1996 it was observed a decline of 98% antibiotic 
usage in fish farms and simultaneously the production of farmed fish increased with more 
than sixty times to 321,257 tons (101). Mainly efficient vaccination is attributed as the factor 
that decreased the antibiotic usage. In the year of 2008 a total of 941 kg of antimicrobial 
agents were prescribed for therapeutic use in farmed fish in Norway. But 65% of the 
prescribed amounts of antimicrobial agents were intended for use on Atlantic cod, a fish that 
holds about 2% of the total production of farmed fish (101). How all this antibiotic usage in 





Materials and methods 
Cloning of MBL from A. salmonicida LFI1238 
The gene encoding A. salmonicida metallo-beta-lactamase had previously been cloned into 
the expression vector pET-26b(+) (Novagen) by researcher Bjørn Altermark. In short the 
restriction sites for NdeI and XhoI were utilized and the gene was cloned without its 
periplasmic leader sequence. Six histidines were added in the N-terminus to facilitate 
purification. The plasmid confers kanamycin resistance and contains a T7 promoter in front 
of the multi-cloning site. The plasmid was transformed into the expression strain Escherichia 
coli Rosetta2 pLysS (Novagen) and kept as a glycerol stock at -80°C. 
Expression of MBL from A. salmonicida 
10 ml LB (Lysogeny Broth) media was inoculated from a glycerol stock of E. coli Rosetta pLysS 
containing the cloned MBL gene. The culture was grown with agitation over night at 370C. 
The overnight culture was used to inoculate 4x250 ml of LB media. The cultures were grown 
at 370C, and their OD 600 nm was measured every hour until it reached 0.5-0.7. Then the 
cultures were induced by adding IPTG (Takara Bio, Otsu Japan) to a final concentration of 0.5 
mM. Induced cultures were grown overnight at 200C with agitation. 
The cells were harvested at 6000 rpm for 25 minutes at 40C. The supernatant was discarded 
and each pellet was resuspended in 30 ml of extraction buffer (50 mM Tris, 250mM NaCl, 5 
mM beta-mercaptoethanol, 10 mM imidazole and 0.1 mM ZnCl2 at pH 7.5) also containing 1 
tablet of protease inhibitor cocktail (Roche, Germany). The cells were transferred to 4 
different 50 ml Sarstedt tubes and frozen at -200C for later use. 
Cell disruption 
DNase (Sigma-Aldrich) and lysozyme (Sigma-Aldrich) were added to the thawed cell 
suspension before sonication. Sonication was performed using a Vibra-Cell VCX 500 (Sonics, 
Connecticut USA), using the following settings; temperature below 200C, amplitude of 25% 
and sonication period 10 seconds on and 10 seconds off for a total of 30 minutes. The 
sonicated cells were then centrifuged in SS34 tubes at 9000g for 30min at 40C and the 




HisTrap FF column  
As the MBL from A. salmonicida was expressed with a Histidine-tag, this will increase the 
affinity to a Histrap column (Pharmacia Biotech, Uppsala Sweden) compared to other native 
proteins. Before putting the protein solution on the HisTrap FF column, the solution was 
filtered using a Millex-GP Filter unit (Millipore, Cork Ireland) with a pore size of 0.22 µm. 
Buffer A contained 200 mM Tris, 0.1 mM ZnCl2, 250 mM NaCl and 10 mM imidazole at a pH 
7.5. Buffer B contained 200 mM Tris, 0.1mM ZnCl2, 250mM NaCl and 500 mM imidazole at a 
pH 7.5. At first, this purification was done with a 5%-100% imidazole gradient over 10 CV, 
and the protein was collected in 1ml fractions. The column size was 5 ml. 
Later the procedure was optimized using a 10%-100% imidazole gradient over 15 CV. 
Fractions were collected based on what seemed to contain most MBL and small amount of 
contamination. 
Dialysis 
The selected fractions were dialyzed using a SnakeSkin Pleated Dialysis tubing (Thermo 
Scientific, Rockford USA) with a cutoff of 3 000 Da overnight in a buffer containing 50 mM 
Tris pH 7.5, 0.1 mM ZnCl2, 250 mM NaCl. This step was used in order to maintain the protein 
in an appropriate and stable solution, especially since imidazole is prone to destabilize 
proteins. As well as purifying the protein, a dilution of the protein is also experienced. 
Increasing the concentration of a protein sample 
After the dialyzing step it was desired to have a higher concentration of the protein before 
doing the next purification step. The protein concentration was increased using an Amicon 
Ultra Centrifugal Filter Unit (Millipore, Cork Ireland) with a cutoff of 10,000 Da, according to 
the Millipore user specifications. 
Concentration measurement 
The Bradford reagent (Bio-Rad, California USA) is diluted 1:5 with MilliQ water. The sample 
with protein and diluted Bradford reagent was then made so the concentration of protein 
was in the range 10-100 µg/ml which was the limits of standard curve of Bovine serum 
albumin (BSA). The measurement was done on the spectrophotometer GeneQuant Pro 
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(Amersham Bioscience, Minnesota USA) at an absorption of 595nm. The protein solution 
was diluted in Bradford Reagent and measured and compared according to the BSA standard 
graph to reveal the protein concentration. 
The protein concentration was also measured using NanoDrop 2000c (Thermo Scientific, 
Rockford USA). The MBL extinction coefficient was determined using the ProtPram tool at 
ExPASy (102), a web based tool which calculates the extinction coefficient using the protein 
sequence. 
Gel filtration 
Gel filtration was carried out using a buffer containing 50 mM Tris pH 7.5, 0.1 mM ZnCl2, 250 
mM NaCl. The motivation for using this purification method was to get as pure protein as 
possible for crystallization and characterizing the molecular mass of MBL and eventually 
other contaminants. The gel filtration was done using a Superdex 75 gel filtation column 
(10/300, Pharmacia Biotech, Uppsala) at a flow rate of 1 ml/min and 1 ml fractions were 
collected. 
Dynamic light scattering 
A Dynamic light scattering (DLS) experiment was done on the DynaPro Dynamic Light 
Scattering system MS/X (Protein solutions, Charlottesville, Virgina USA) with dialyzed protein 
which had been concentrated to 10 mg/ml. Before performing the experiment, the protein 
was diluted to 5 mg/ml. The measurements were done at temperatures of 4, 9, 14, 19, 24, 
29, 34 and 390C. At each temperature 20 measurements were done. 
SDS-PAGE 
SDS-PAGE or sodium dodecyl sulfate polyacrylamide gel electrophoresis is a technique which 
separate proteins according to their electrophoretic mobility using an electric field. 
After each purification step, SDS-PAGE was performed on various fractions which were 
loaded on a 4-20% Pierce Precise Protein Gels (Thermo scientific, Rockford USA) and run 
according to manufacturer’s protocol and Laemmli 1970 (103). 
A Loading Dye (LD) consisting of (1ml); 750µl NuPage LDS sample buffer (Invitrogen, 
California USA), 100µl MilliQ water and 150µl beta-Mercaptoethanol was used. Each sample 
was made with 20µl protein solution, which was diluted in case of high protein 
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concentration, and 5µl LD. Before the samples were applied on the gel they were heated at 
950C for 5 minutes. The instrument (X-Cell SureLock Electrophoresis Cell) was assembled and 
Tris-Hepes-SDS buffer (Thermo scientific, Rockford USA) was used. The different samples, 
and one reference lane consisting of 10µl molecular weight marker Mark12 Unstained 
Standard (Invitrogen, California USA), were loaded in the wells. The gel was run at 140V for 
45 minutes. Afterwards, the gel was rinsed in MilliQ water and heated in a microwave oven 
for one minute and put on an orbital shaker for one minute. The water was then discarded, 
and the water rinsing step was repeated twice. SimplyBlue Safe-Stain (Invitrogen, California 
USA) was poured on the gel and heated in the microwave oven for one minute and put on an 
orbital shaker for approximately 7 minutes. The stain was discarded and the gel was again 
put in MilliQ water. 
Crystallization trials 
Crystallization trials were set up using protein which had been concentrated to about 10 
mg/ml. These trials were done both manually and with a crystallization robot. 
11 different screens made by researcher Kenneth Johnson were set up with a Phoenix DT 
crystallization robot (Rigaku, Sendagaya Japan); using sitting drops containing 200 nl of 
concentrated protein solution and 200 nl reservoir solution or 100 nl of concentrated 
protein and 100 nl reservoir solution. 
Crystal screening was also conducted manually with the Crystal screen and Crystal screen 2 
(Hampton Research, Aliso Viejo, California USA) and JCSG-plus screen (Molecular 
dimensions, Suffolk United Kingdom) with hanging drops containing 1 µl protein solution and 
1µl reservoir solution with a reservoir volume of 500 µl. 
Alignment 
A BLAST (104) search was performed using A. salmonicida MBL as a search sequence. The 
four most similar sequences were downloaded together with IMP-1 from Pseudomonas 
aeruginosa which was the most similar MBL with known crystal structure. The different 
sequences were aligned using the T-Coffee Multiple sequence alignment tool (105). Also a 
prediction of asMBL secondary structure was done using the PSIPRED web server (106). 
Secondary structure of IMP-1 was retrieved from Protein Data Bank (107) using the entry 
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PDB ID: 1DD6 (17). The sequence alignment and the structure predictions were visualized 
using the ESPript web server (108). The numbering of the different amino acid position was 
done according to Garau et al (109) proposition of standard numbering for class B beta-
lactamases.  The presence of an N-terminal signal peptide was analyzed using Signal P 3.0 
web tool (110). 
Polymerase chain reaction 
Polymerase chain reaction (PCR) is a technique which amplifies a target gene sequence using 
primers complementary to the target region and a DNA polymerase that assembles new 
DNA strands from nucleotides. Repeated heating and cooling, or thermal cycles, are used to 
respectively separate the DNA strands and amplify the target DNA by DNA polymerase. 
The degenerate primers MBL-F1 (CAYTTTCATGAAGAYCAAAC) and MBL-R1 
(GCAYCACCWGTCCASCCAAT), which were constructed by Bjørn Altermark based on selected 
MBL nucleotide sequences, were used to screen various Aliivibrio isolates from both the 
aquaculture industry and from wild fish caught in the Barents Sea. The letters represent the 
different nucleotides, see table 2. If positive, the PCR should give a 300 nt product. 
Table 2 The IUPAC standard code for nucleotides 





Y C or T 
S G or C 





A typical amount of reagents for one reaction mixture made for PCR: 
Water     36.7 µl 
dNTP mix    1 µl 
Taq Polymerase   0.3 µl (1.25 units) 
Buffer (10X)    5 µl 
MgCl2 (25mM)   3 µl 
Template (genomic 100 ng/ml)  1 µl 
Primer (10 µM)    1.5 µl forward, 1.5 µl reverse 
TOTAL:     50 µl 
 
The chemicals used to make the reaction mixes were; dNTP mix F-560 (Thermo Scientific, 
Rockford USA), Taq polymerase (VWR, Dublin Ireland), Thermo Pol buffer (New England 
biolabs, Ipswich USA). 
All solutions, except Taq polymerase, were vortexed and centrifuged before being added to 
the reaction mixture and each test tube was mixed and centrifuged before being loaded on 
the PCR machine PTC 200 DNA Engine (Ramsey, USA), which had the following settings: 
• 3 minutes at 940C for initial denaturation 
• 30 cycles which includes: 
o 30 s at 940C for denaturation 
o 30 s at 520C for primer annealing 
o 2 min at 720C for extension process 
• Ending the program with 7 minutes at 720C. 
The test tubes were put on ice after the program had finished. 
The agarose gel was made of a solution containing 1% agarose and 0.01% GelGreen nucleic 
acid stain (Biotium, Hayward California USA) in Milli-Q water. The solution was heated in a 
microwave oven until it was homogeneous. The homogeneous solution was put in an 
agarose gel container with a well comb for an hour to solidify. The samples which were 
applied to the agarose gel were made of 50 µl samples from the PCR test tubes and 7 µl TAE 
(Tris-acetate-EDTA) loading buffer. And together with the different samples also a 1 Kb DNA 
Ladder (Invitrogen, Carlsbad California USA) was applied. The agarose gel was then run at 90 
V for an hour. 
Activity test using nitrocefin 
To identify purification fractions containing MBL, a nitrocefin (Merck, Darmstadt Germany) test 
was performed on the fractions of interest. A test solution was made with 980µl buffer 
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(250mM NaCl, 50mM Tris pH 7.5, 0,1mM ZnCl2), 10µl nitrocefin and 10µl of protein sample. 
After approximately 5 minutes it could be concluded if the MBL activity was present in the 
specific fraction. As the native color of nitrocefin is yellow, a test solution which after 5 
minutes still would look yellow was concluded to not contain MBL. While developing a red 
color during the 5 minutes, this would indicate the presence of MBL in the fraction. 
Assay for MBL with nitrocefin 
The appropriate wavelengths for measuring quantity of the substrate, nitrocefin, and 
product were found by comparing wavelengths found in literature from Hu et al (111) and 
Lisa et al (112), and making experimental measurements of their absorbance spectrum. 
From experiments the wavelength for measuring substrate was at 395 nm and the 
wavelength for measuring product was at 485 nm. All measurements were done using a 
Spectramax M2e (Molecular devices, Sunnyvale California USA). 
Preparation of the substrate nitrocefin 
As suggested by the manufacturer, nitrocefin was dissolved in DMSO solution. The 
concentration of nitrocefin in solution was 2 mM. 
Zinc-influence 
The reaction mixture used when testing Zinc-influence was 0.5 M NaCl, 10 mM Tris, 0.2 mM 





To observe the influence of reducing agents on the enzyme, 5mM of beta-mercaptoethanol, 
DTT (Dithiothreitol) or TCEP (Tris(2-carboxyethyl)phosphine) was added to a reaction 
mixture containing 0.5 M NaCl, 10mM Tris, 25 µM ZnCl2 and 10 µl 20 µg/ml MBL at pH 7.5 in 
370C.  The reaction mixture was equilibrated for 5 min at 370C before starting the reaction by 
adding 0.2 mM nitrocefin. 
pH optimum 
The optimal pH for MBL was identified using only Hepes buffer in the pH range 6.5-8.5 
because of the interactions of between buffer molecules found on the substrate, which will 
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be discussed in more detail later. The experiment was done in a reaction mixture containing 
0.5 M NaCl, 0.2 mM nitrocefin, 50 mM Hepes, 100 µM ZnCl2 at room temperature (22
0C). 
pH and Tris influence on substrate 
Reaction mixture was as follows; 0.5 M NaCl, 100 µM ZnCl2, 0.2 mM nitrocefin and 50 mM 
buffer (Tris and Hepes). Experiment was done at room temperature (220C). 
NaCl optimum 
The search for the optimal concentration of NaCl for MBL activity was done in a reaction 
mixture with 25 µM ZnCl2, 10 mM Tris, 0.2 mM nitrocefin at pH 7.5 at 37
0C. The enzyme was 
incubated in reaction mixture at 370C for 5 minutes before adding substrate. 
Temperature optimum 
The reaction mixture was made of these components: 0.2 mM nitrocefin, 25 mM Hepes pH 
7.5, 200 µM ZnCl2 with concentrations of NaCl at 0 M, 0.2 M and 0.5 M. 
The experiment was carried out having the reaction mixture set to the intended 
temperature before adding enzyme. After 10 minutes the reaction was stopped by adding 
EDTA and putting the mixture on ice before measuring its endpoint activity by the 
spectrophotometer. 
The blanks for this experiment were made without added enzyme. The blank solution had 
the same components as the reaction mixture for finding temperature optimum, including 
the same amount of EDTA. From these measurements an assumption of the stability of the 
substrate was found. 
Refolding of protein 
The refolding capability of the protein was analyzed in a reaction mixture containing 0.5 M 
NaCl, 100 µM ZnCl2, 50 mM Hepes and 0.2 mM nitrocefin at pH 7.5 with 10 µl 0.2 mg/ml of 
asMBL. The protein (0.2 mg/ml) aliquoted into 0.2 ml tubes, were incubated at 600C and 
samples were taken out after 5 minutes, 10 minutes and 30 minutes. After incubation the 
tubes were put on ice for 30 minutes before being assayed using nitrocefin. A solution not 




The different substrates were dissolved in solution of 50 mM Hepes pH 7.2 and 100 µM 
ZnCl2. The substrate concentration of this stock solution was decided using the 
spectrophotometer and extinction coefficient of each substrate. Based on the concentration 
of stock solution the solutions for the kinetic analysis were made in the range of 2-1,000 µM. 
The kinetic analysis was performed in a reaction mixture containing 50 mM Hepes pH 7.2 
and 100 µM ZnCl2 and measured on a SpectraMax using 96 well falcon UV microplates (BD 
Biosciences, USA) on all substrates, except nitrocefin in which case the 96 well flat bottom 
non-binding surface (Corning, Edison, New Jersey USA) was used. Incubation of the reaction 
mixture was done for 5 minutes at 300C. The extinction coefficients, wavelengths and also 
plate specific extinction coefficients were kindly provided by researcher Ørjan Samuelsen, 
and those used during this experiment are mentioned in table 3.   
Table 3 Extinction coefficients for substrate concentration determination, plate specific coefficient for determination of 
Vmax and kcat and wavelengths for the different beta-lactams. *= Extinction coefficient not calculated. Numbers were 









Meropenem -6,500 0.00306 300 
Imipenem -9,000 0.00347 300 
Ertapenem -6,920 0.00710 300 
Nitrocefin 17,400 0.00645 482 
Cefuroxime -7,600 0.00252 260 
Cefepime -10,000 0.00392 260 
Ceftadizime -9,000 0.00431 260 
Cefoxitin -7,700 0.00231 260 
Piperacillin -820 0.000344 235 
Aztreonam -700 -* 320 
  
The results of the kinetic analysis were processed in Microsoft Excel using solver, an 
algorithm that can be used for non-linear regression. This method which was used is based 
on a general description on how to solve non-linear regression in Microsoft Excel (113). 
Screening of inhibitors 
Inhibitors in solid state were kindly provided by researcher Hanna-Kirsti Schrøder Leiros. 
These were solved in MilliQ water, and some of the less water soluble inhibitors were 
ionized using NaOH. The reaction mixture of each inhibitor contained: 0.5 M NaCl, 100 µM 
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ZnCl2, 50 mM Hepes at pH 7.5 and 1 mM of the inhibitor. The reaction mixture was 
incubated at 5 min at 300C, before enzyme was added. The pH of each reaction mixture was 






The protein was first purified using His trap column at 5-100% imidazole gradient which later 
was optimized into a 10-100% imidazole gradient. As seen from the chromatograms before 
(figure 18) and after the optimization (figure 19) two peaks have become one peak, 
indicating that more impurities have been separated.  The peak representing MBL has an 
absorption of about 250 mAU and has a ledge present in the beginning of the peak, 
indicating a presence of impurities in the first fractions of the peak. It seems like the 
optimization has positive influence on the ledge, the peak representing the ledge has an 
absorption of about 200 mAu before optimization and about 30 mAu after optimization 
(absorption at 280 nm), but it seems like the ledge is stretched out. Based on the protein 
sequence the mass of asMBL is predicted to be about 26 kDa. From the SDS PAGE gel picture 
(figure 20) the strong band is in the expected area between 21.5 and 31 kDa. MBL activity of 
these fractions was tested using nitrocefin as substrate and proved to be positive. Some 
impurities can be spotted on SDS PAGE gel picture (figure 20), but the gel was overloaded 
with protein sample and impurities will be more visible. The most troublesome impurities 
are those with higher molecular weight than 10,000 Da, since these will not be dispatched 
when accomplishing dialysis, because of dialysis cutoff limit of 10,000 Da. The impurities are 
most present in the earliest fractions and fades away as the gradient increases. 
Activity of fraction 16 and 25 was tested. Fraction 16 showed some MBL activity and fraction 




Figure 18 HisTrap purification with a 5%-100% imidazole gradient using a HisTrap FFcolumn (5 ml) over 10 CV with a flow 
rate of 1 ml/min and collection of 1 ml fractions. The brown line indicates the gradient and the blue line indicates the 
absorption at 280 nm. Different peaks are marked, those peaks with impurities display impurities which were washed 
away at the 5% step and which impurities that were washed away during the gradient. Collected fractions are marked in 
red along the x-axis. Absorption in mAu is marked along the y-axis and eluted volume in ml is marked along the x-axis. 
 
Figure 19 His-trap purification with 10%-100% imidazole gradient, using a HisTrap FFcolumn (5 ml) over 15 CV with a flow 
rate of 1 ml/min and collection of 1 ml fractions.   The brown line indicates the gradient and the blue line indicates the 
absorption at 280 nm. Peaks with ledge and MBL are marked. Collected fractions are marked in red along the x-axis. 






Figure 20 Gel picture from His Trap purification with 10%-100% gradient. 
Gel filtration 
For the column used for gel filtration (Superdex 75 gel filtation column (10/300) a protein 
weighing 67 kDa would elute at about 9-10 ml (114). From the chromatographs an elution of 
MBL at around 8 ml can be observed (figure 21). Heavy material elutes faster than lighter 
material, which indicates that the protein is unstable and most likely is in an aggregated 





Figure 21 Chromatograms from gel filtration of asMBL using a Superdex 75 gel filtration column (10/300) at a flow rate of 
1 ml/min and 1 ml fractions were collected. Collected fractions are marked in red along the x-axis. Absorption in mAu is 
marked along the y-axis and eluated volume in ml is marked along the x-axis. 
Crystallization 
To obtain a structure of asMBL crystallization trials were set up, both manually and with 
robotic help. The proteins used for these trials were from after the dialysis step, not the gel 
filtration step because of apparent problems with soluble aggregation. From present studies 
no crystals from these trials is observed.  
PCR 
The molecular weight standard used for the preparation of this agarose gel do not show a 
good separation of the different bands, but give an general impression of the size of the PCR 
products (figure 22). The PCR products of all MBLs from Aliivibrio species associated with fish 
industry (A) and two Aliivibrio species found in environment untouched by human influence 
seems to be in proximity with molecular weight band of 298 nt, which coincides with the 
expected product of 300 nt. The band from the positive control also supports that the 
product from the Aliivibrio species is MBL. 
Some unspecific bands of higher nt is present in those Aliivibrio species that do not seem to 





Figure 22 PCR result. MW= molecular weight marker, NC = Negative control, PC = Positive control A =Aliivibrio 
salmonicida from marine aquaculture, B = Aliivibrio species from Barents Sea fish. 
Sequence alignment 
5 different sequences, which included MBLs from Aliivibrio salmonicida, Shewanella 
sediminis, Pseudomonas Aeruginosa, Photobacterium profundum and Vibrio fischeri, were 
downloaded and aligned. The sequence numbering is based on the BBL classification scheme 
and some gaps are introduced in the aligned sequence to make it fit to the classification 
scheme (colored triangles in figure 23). Some residues were surplus compared to the BBL 
classification and is marked with letters a, b, c, d and so on. 
From the overall look at the sequence alignment in figure 23 it is rather easy to spot the 
conserved amino acids (residues in red blocks). The most interesting and highly conserved 
amino acids are those participating in the catalysis of the beta-lactam ring. Those conserved 
amino acids marked in figure 23 are amino acids responsible for the binding of the two Zn2+ 
ions; His106, His118 and His196 coordinate Zn1 and Asp120, Cys221 and His263 coordinate 
Zn2.  
When comparing the prediction of the secondary structure of A. salmonicida and the 
secondary structure of IMP-1 the predicted secondary structure has a high degree of 
resemblance to the structure of IMP-1. All alpha-helices are predicted in the same area, and 
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more or less all beta-sheets are found in the same regions. This indicates that the structure 
of MBL from A. salmonicida would look similar to the structure of IMP-1. 
In the sequence of asMBL the signal sequence is included, as this protein is transported to 
the periplasmic space of the bacteria (115). Using a prediction tool, it was found that the 
signal peptide probably includes the amino acids from Met0a to Ala36, as indicated in figure 
23. An interesting point is that an alpha helix is predicted in the same region as the predicted 
signal peptide. As seen in the other MBLs they all are predicted to have a signal peptide. 
IMP-1’s signal peptide is not shown as it is not part of the downloaded sequence, as the 
sequence originates from a structure of IMP-1. The cleavage site of the different MBLs are 
not conserved, for asMBL it was predicted to be between Ala28 and Ala36, for ssMBL it was 
predicted to be between Ala29 and Glu30 or Leu12 and Arg13, for ppMBL it was predicted to 










Zinc is important to MBL as the enzyme is inactive without Zn2+ bound to it (figure 24). This is 
shown in the temperature experiments when EDTA is added to the reaction mixture and 
stops the hydrolysis reaction, which have been shown for other MBLs as well (116). It seems 
that the concentrations of zinc have no impact as long as the enzyme has its minimum 
concentration of zinc (28). 
 
Figure 24 D10 is blank (no enzyme added), while E10 has 100 µM ZnCl2 and F10 has 5mM ZnCl2. 
Reducing agents 
In the presence of the reducing agents DTT, beta-mercaptoethanol and TCEP the activity of 




Figure 25 A12 is a blank, while B12 has no reducing agent added to the reaction mixture. To the other reaction mixtures a 
reducing agent has been added; C12 and D12 contain beta-mercaptoethanol, E12 and F12 contain DTT and G12 and H12 
contain TCEP. 
pH optimum 
asMBL has a broad pH range where the activity is at its best (figure 26). Compared to the pH 
in coastal water, pH 8.0-8.3, it is expected of asMBL to have optimal activity in this range. It 
was the intention of this experiment to test the activity at higher pH than done in this study, 
but as mentioned in Nitrocefin - Tris reactivity and pH stability, nitrocefin is not stable at high 
pH and some buffers seem to destabilize nitrocefin more than others. 
 
 
Figure 26 Activity vs. pH for asMBL in Hepes buffer in the range of pH 6.5 to 8.5. All points are relative to the average 
activity measured at pH 7.5 (100%). The antenna at each measured pH displays the range of enzyme activity measured. 
Time (secs)






Well A12 B12 C12 D12 E12 F12 G12 H12
Vmax 3,555 78,711 62,566 59,926 46,568 49,549 0,715 -4,605
R^2 0,747 0,994 0,999 0,984 0,997 0,999 0,075 0,792






























As this protein is collected from a bacterium which thrives in the sea, an interesting point is 
to see how the protein is adapted to salt. Since the sea water has a salinity of about 0.5 M 
NaCl it was expected that the optimal salt conditions for asMBL would be somewhere 
around this value. As can be seen from figure 27 the salt optimum for asMBL is 0,5 M NaCl, 
as expected, but the range of its optimal salt condition for its activity is very broad, having a 
range of 0,5-2 M NaCl. Even at salt concentrations of around 2.5 M NaCl the activity is about 
90% of its optimal NaCl activity.  
The optimal salt conditions for asMBL were compared to the optimal salt conditions for VIM-
2, a MBL originating from P. Aeruginosa a bacteria which has shown to be pathogenic in 
humans (117). As this organism thrives in blood stream conditions, an optimal level of 
salinity would be 0.6% (118) or about 0.1 mM NaCl. From figure 27 it can be stated that VIM-
2 has an optimal NaCl concentration of 0.2 M NaCl for its activity, which is lower compared 
to asMBL. VIM-2 does not show the same degree of salt tolerance as asMBL, as the activity 
drops more quickly in a nearly linear fashion after reaching its optimal salt concentration. 
 
Figure 27 The salt optimum for asMBL and VIM-2. All residual activities are relative to the highest average activity for its 
separate enzyme. For asMBL the highest activity is at 0.5 M NaCl, while for VIM-2 it is at 0.2 M NaCl. The other measured 
NaCl concentrations are 0, 1, 1.5, 2, 2.5, and 2.8 M. At each salt concentration, the uncertainty is given as the range of 
activity measured. Other salt optimum trials for asMBL showed a good salt tolerance (approximately 80%) up to 3.5 M 
NaCl (not shown). It is a clear difference between the psychrophilic, marine MBL and mesophilic, terrestrial MBL. The 































In these experiments the goal was to find the optimal temperature for the asMBL and VIM-2, 
compare the values and see how different concentrations of salt affect the temperature 
optimum. 
The highest activity shown for asMBL and VIM-2 is at 0.5 M and 0.2 M respectively. At both 
of these salt concentrations asMBL has a lower optimum temperature than VIM-2 (figure 28 
and figure 29); at 0.2 M NaCl asMBL and VIM-2 have an optimal temperature of 30
0
C and 
400C respectively and for 0.5 M NaCl the values are shifted to 350C and 45-500C respectively. 






Figure 28 Comparison of temperature optimum for activity at 500 mM for asMBL and 
VIM-2 and also the stability of nitrocefin depending on the temperature. Activity was 
measured at the temperatures; 4, 10, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80 and 900C. All 
the measurements in a series were set relative to its series maximum value. For asMBL it 
was at 350C and for VIM-2 it was at 450C. The values of substrate stability 
measurements were relative to the maximum value of the asMBL series. The range of 
measured enzyme activities is displayed by the antennas. 
 
Figure 29 Comparison for temperature optimum for asMBL and VIM-2 at 200 mM NaCl. 
The measured temperatures were; 20, 25, 30, 35, 40, 45, 50 and 60 degrees Celsius. All 
measurements were made relative according to the maximum value of its series. The 
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Comparing asMBL and VIM-2 






The amount of salt present affects the optimal temperature for the enzyme activity. This is 
imminent in both asMBL and VIM-2 (figure 30 and figure 31). For both of the enzymes the 
optimal temperature is lowered by approximately 5-10 degrees when lowering the salt 
concentration from 0.5 M to 0.2 M. From figure 30 it can be spotted a recess of overall 
activity when lowering the salt concentration, which correlates to the NaCl optimum of 
asMBL (figure 27). VIM-2 has its highest measured activity at 400C and 200 mM NaCl (figure 
31), which also correlates to the NaCl optimum of VIM-7 (figure 27). 
Another point of interest is the stability of the substrate nitrocefin at higher temperatures. 
As seen in figure 28, nitrocefin decays at higher temperatures as it is being turned into 
product. The instability of nitrocefin is not a problem at temperatures ranging from 100C to 
600C, while at higher temperatures it could have impact on the result, if the blank value is 
not subtracted from the measured value. For instance, at 700C the blank value is OD of 
0.174, while the other blanks at lower temperature have values of 0.13. Without this 
correction of blanks, the average measured enzyme activity at 700C for asMBL would seem 
to be unexpectedly higher than the average measured enzyme activity at 600C for asMBL. At 
the temperature of 900C the instability of nitrocefin is quite high with a value of OD of 0.405, 




Figure 30 Presentation of how asMBL's optimal temperature for activity differs 
according to NaCl concentration. Activity was measured at the temperatures; 4, 10, 15, 
20, 25, 30, 35, 40, 50, 60 and 70
0
C. All measurements were made relative according to 
optimal temperature at 500 mM NaCl. The range of measured enzyme activities is 
displayed by the antennas. 
 
 
Figure 31 The optimal temperature for VIM-2 activity at different concentrations of NaCl. 
The activity was measured at the temperatures; 4, 10, 20, 30, 35, 40, 45, 50, 60 and 70
0
C. 
All measurements were made relative according to optimal temperature at 200 mM 

























Comparing the asMBL's 




























Temperature influence at 






Nitrocefin - Tris reactivity and pH stability 
Nitrocefin stability was tested of various pH, temperature and Tris concentrations. Its 
stability at different temperature has already been shown. 
From figure 32 a relation between pH and auto-hydrolysis is seen, higher pH increases the 
auto-hydrolysis, but only seen together with the buffer Tris. When nitrocefin is present in 
Hepes buffer no auto-hydrolysis is observed at any pH, the exception is some auto-hydrolysis 
at pH >8 after two hours. 
A comparison of pH and concentration of Tris was made at figure 33. The amount of Tris 
present has influence on the rate of nitrocefin auto-hydrolysis to a certain degree. At 
concentrations of Tris from 0.08 M and beyond do not affect the rate of nitrocefin auto-




Figure 32 The difference of stability of nitrocefin in Tris and Hepes buffer. All 
measurements were made relative to measurement made with Tris at pH 9. 
 
Figure 33 Tris concentration and different pH influence the stability of nitrocefin. All 
points are relative to the highest measurement done at pH 9 with 25 mM Tris. The 
activity measurement done at pH 7 was set as blank for the experiment on pH influence 
on nitrocefin, since it is about the same level as the other blanks for the experiments 
with different Tris concentrations. pH and Tris concentrations are marked at the 


































































Nitrocefin stability in different 








Results from these experiments showed no apparent refolding of asMBL. Solutions 
incubated at 60
0
C had no activity compared to the solution which was not incubated. 
Kinetics 
Results from the kinetic study in this report were compared to similar MBLs from functional 
group B1 (table 4).  The MBLs which were focused on was IMP-1 from Pseudomonas 
aeruginosa (116) because of its sequence similarity and VIM-2 from Pseudomonas 
aeruginosa (119) because of the characterization done in this study. Also a study involving 
VIM-7 was included (120), since its kinetic characterization is done at the most similar 
conditions as the kinetic characterization done for asMBL. 
asMBL hydrolyzed more or less all beta-lactam antibiotics, except from the monobactam 
aztreonam and the penicillin piperacillin (see table 4 and figure 34-42).  


















 for the same substrates. 
IMP-1 is the MBL solved structure which has the most similar amino acid sequence as 
asMBL, but their kinetic constants are very different. Generally asMBL has both higher Km 
and lower kcat than IMP-1. 
When comparing the performance constants for the different substrates, asMBL seems to 
have a better affinity for carbapenems than cephalosporins and cephamycins, in which 
cefuroxime is an exception. Nitrocefin is secluded from this comparison as it is made to be 
readily hydrolyzed. Piperacillin is a penicillin which is used as an extended spectrum 
antibiotic, which could explain asMBLs apparent inability to hydrolyze penicillins in this 
study. As long as this is the only penicillin substrate in this study there is no definite 
conclusion about asMBL’s capability of hydrolyzing penicillins in general.    
The presence of 0.5 M NaCl in the reaction mixture raised asMBL’s performance constant for 
the hydrolysis of ertapenem. The improvement in the performance constant, when having 
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salt present, is not caused by a rise in kcat, but a lowering of the enzyme affinity, Km (table 4 





Figure 34 Enzyme kinetics for Cefoxitin using 100 nM enzyme. 
 
Figure 35 Enzyme kinetics for Cefuroxime using 10 nM enzyme. 
 
Figure 36 Enzyme kinetics for Cefuroxime using 100 nM enzyme. 
 





























































































































Figure 38 Enzyme kinetics for Nitrocefin using 10 nM enzyme. 
 
Figure 39 Enzyme kinetics for Meropenem using 100 nM enzyme. 
 

































































































Figure 41 Enzyme kinetics for ertapenem at 0 mM NaCl using 10 nM enzyme. 
 
Figure 42 Enzyme kinetics for ertapenem at 500 mM NaCl using 10 nM enzyme. 
 
Figure 43 Difference in enzyme kinetics with various NaCl concentrations. The enzyme concentration was 10 nM. Vmax when having 0 mM NaCl and 500 mM NaCl is regarded as the same 























































































Enzyme kinetics for Ertapenem at 0 mM and 500 mM NaCl
Ertapenem 0 mM NaCl




Table 4 Comparison of kcat, Km and performance constant for asMBL (in bold, values from current work), IMP-1, VIM-2 and VIM-7 (values from literature). The kinetic parameters for VIM-2 
had standard deviations that always were <10%. NA=Results not available, NM=No activity measured, ND=Not determined. 
 kcat (s-1) Km (µM) kcat/Km (1/µM*s) 
Substrate asMBL IMP-1 VIM-2 VIM-7 asMBL IMP-1 VIM-2 VIM-7 asMBL IMP-1 VIM-2 VIM-7 
Meropenem 13.3 ± 5 50 ± 5 5 42 ± 0.8 142 ± 
100 
10 ± 2 2 38 ± 4 0.94 0.12 2.5 1.1 
Imipenem 7.95 ± 
0.6 
46 ± 3 9 100 ± 2 933 ± 70 39 ± 4 34 27 ± 2 0.0085 1.2 3.8 3.7 
Ertapenem 3.9 ± 1 NA NA 8 ± 0.2 73 ± 30 NA NA 28 ± 3 0.054 NA NA 0.29 
Ertapenem 
(NaCl) 
4.3 ± 0.4 NA NA NA 17 ± 7 NA NA NA 0.25 NA NA NA 
Nitrocefin 6.3 ± 0.6 63 ± 10 18 1,500 ± 
29 
6.2 ± 3 27 ± 3 770 58 ± 3 1.0 2.3 43 26 
Cefuroxime 10.7 ± 3 8 ± 1 20 16 ± 0.5 68 ± 30 37 ± 3 8 29 ± 4 0.16 0.22 0.40 0.55 
Cefepime 0.581 ± 
0.005 
7 ± 0.5 >400 5.3 ± 0.2 177 ± 14 11 ± 1 >40 580 ± 61 0.0033 0.66 0.10 0.0091 
Ceftadizime 0.089 ± 
0.03 
8 ± 1 72 1.4 ± 0.1 37 ± 12 44 ± 3 3.6 120 ± 25 0.0024 0.18 0.0500 0.012 
Cefoxitin 0.27 ± 
0.09 
16 ± 1 13 10 ± 0.3 79 ± 30 8 ± 1 15 68 ± 7 0.0034 2 1.2 0.15 
Piperacillin NM ND 125 140 ± 13 NM ND 300 26 ± 3 - 0.72 2.4 5.4 
Aztreonam NM >0.01 >1,000 NM NM >1,000 >0.01 2,700 ± 
630 





Potential inhibitors belonging to the molecular groups of thiophenes, pyrroles and pyridines 
and also the known beta-lactamase inhibitor clavulanic acid (figure 44), were screened. The 
definition of an inhibitor in this study is substance that induces a 50% lesser activity 
compared to normal activity. From table 5, it can be observed that some of the potential 
inhibitors have effect on the MBL; 2-picolinc acid, 2,6-pyridine-di-carboxylic acid, pyridine-
2,5-dicarboxylic acid and 2-pyridinecarboxylic acid. But many of these molecules are known 
to chelate divalent cations, therefore it is doubtful that they have any inhibitor effect 
besides their chelating capabilities. 
 
Figure 44 Structures of all inhibitors tested against asMBL. 
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Table 5 List of all inhibitors tested and their inhibitory effect. * = Inhibitory effect was measured, but there is uncertainty 
if it is interacting with enzyme or just acting as chelating agents. 
Inhibitor Inhibitory effect 
Thiophene-2-caboxylic acid No 
5-Methylthiophene-2-carboxylic acid No 
3-Methylthiophene-2-carboxylic acid No 
5-Bromo-2-thiophenecarboxylic acid No 
Benzo[B]thiophene-2-carboxylic acid No 
2,5-Thiophenedicarboxylic acid No 
Pyrrole-2-carboxylic acid No 
Indole-2-carboxylic acid No 
2-Picolinic acid Yes* 
2,6-Dipicolinic acid Yes* 
2,5-Pyridinedicarboxylic acid Yes* 
3-Hydroxypicolinic acid Yes* 
2-Quinolinecarboxylic acid No 






Classification of asMBL 
Based on the sequence alignment performed in this study (figure 23) the conserved amino 
acids being ligands for the two zinc ions are identical with respective amino acids found in 
molecular class B1. Additional characterization information supports this view as the amount 
of zinc present does not affect the hydrolyzing capabilities of the enzyme as long as there 
presumably is a minimum concentration of zinc present. This indicate that the enzyme truly 
is a metallo-beta-lactamase which belongs to the molecular class 3 and it does not belong to 
the molecular class B2 which is inhibited by two zinc bound to the active site.  
From the results already mentioned above regarding molecular classification it is strongly 
indicated that the enzyme belongs to the functional group 3a, since most MBLs molecular 
classified as B1 or B3 belongs to this class. asMBL is not inhibited clavulanic acid, but is 
inhibited by EDTA, which proofs that this enzyme belongs to the functional group 3. The 
enzyme kinetics indicates that asMBL readily hydrolyses all beta-lactam substrates, except 
monobactams, which supports that this enzyme belongs to the functional class 3a, even 
though this study does not show if this enzyme hydrolyze penicillin substrates. 
Reductive environment 
The reducing agents DTT, beta-mercaptoethanol and especially TCEP are presumably 
affecting asMBL capability to hydrolyze. A reason for this behavior could be that they reduce 
the catalytic important residue Cys221. Their potential to reduce a disulfide bond is in 
increasing order of reduction potential; beta-mercaptoethanol has reduction potential of -
0.26 volts (121), DTT has a reduction potential of -0.33 volts (122) and TCEP has no reduction 
potential as posphines reduce disulfide bonds via an irreversible pathway (123), but TCEP 
has been found to be more reductive than DTT and BME (124). As the reduction potential of 
these compounds increases so do their inhibition of asMBL activity. Since all these reducing 
agents are known to have its influence on cysteine, this strongly indicates that Cys221 is 
affected so it cannot coordinate Zn2 and inhibit the activity of asMBL. Another possibility is 
that these reduction agents do not affect asMBL, but affect nitrocefin in such way that the 
enzyme faces difficulties when trying to hydrolyze this substrate. Also the zinc ions could be 
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affected in such way that they experience a reduction from Zn2+ to the solid Zn. When zinc is 
in solid form it will be unavailable for asMBL and a decline of hydrolysis would occur. But 
during the experiment there was no apparent sign of solid material in the reaction mixture, 
which would be expected in the case of formation of solid zinc. 
The periplasm of the cell, which asMBL is directed to, is an oxidative environment. The 
results based on asMBL encountering reductive environment indicate that the enzyme is 
adapted to this. 
Purification and crystallization 
When performing the His trap purification step it seems like changing the gradient from 5%-
100% to 10%-100% optimized the purification of asMBL. There is still a ledge of impurities 
present, but it would be difficult to optimize this step further. The ledge could be separated 
by extending the gradient by increasing the amount of column volumes this gradient goes 
through. It is not certain that this will separate the ledge entirely, and it would probably be 
easier to separate the impurities by going through a gel filtration step.  
An initial goal of this study was to obtain a structure of asMBL. As crystallization trials 
demand a large quantity of pure protein, it was initially recommended to do a gel filtration 
of the protein before doing the crystallization trials. This proved to be difficult as the protein 
seemed to have been aggregating on the gel filtration column. Even though the protein was 
not entirely pure after the His-trap filtration step, it could hopefully turn out to be pure 
enough for crystallization trials. Results from the different trials showed no promising results 
as there was a majority of aggregation encountered and the DLS experiment indicated that 
the protein was in an aggregated form. Some aggregation was encountered when having the 
protein in refrigerator, but the protein was still present in solution during storage. When 
storing the protein it was kept in low concentration of about 0.2 mg/ml, while the protein 
concentration in gel filtration and DLS experiment was about 5-15 mg/ml. Even though no 
visual aggregation has been observed in large scale, this could indicate that the protein is in 
a soluble aggregated form. But the protein has shown good hydrolyzing capabilities, so it 
seems like the protein is in a proper condition when in low concentration.  
The protein has shown to be unstable and have a potential for forming aggregates at high 
protein concentrations. There could be many reasons for the instability of the protein. One 
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of the reasons has its background in the protein construct for expression which consists of a 
non-cleavable histidine-tag that can render the protein unstable and cause aggregation. 
Another factor which can affect the protein’s stability is its storage and purification buffer. 
This protein has proved to have a broad tolerance of salt in regards of activity and higher 
concentration of salt could affect the salting out effect of the protein, making it more stable 
for storage at higher protein concentrations. The last point, which is the crystallographer’s 
nightmare, is that the protein itself does not maintain a proper stabilization at high protein 
concentration. Little is known about the general protein behavior and stability, and still 
much of its properties are hard to predict and understand. 
NaCl vs. temperature 
MBLs are directed to the periplasm or extracellular space and in the case of asMBL this 
means that the enzyme is exposed to marine environment and have to necessarily be 
differently adapted compared to enzymes existing in other environments (34). 
Salt seems to be important for asMBL activity and because of its tolerance of high 
concentrations of salt this enzyme could be suggested to be a halophilic enzyme. But as most 
halophilic enzymes are deactivated by NaCl or KCl concentrations of less than 2 M (36, 37), 
at very least this enzyme can be classified as a very salt tolerant enzyme. VIM-7 is also quite 
salt-tolerant as it still has 50% relative activity, compared to optimal activity, at 1.5 M salt. It 
could be a general feature of MBLs to be tolerant to high concentrations of salt. 
In this study the mesophilic VIM-7 and the psychrophilic asMBL were compared in regards of 
temperature optimum under different salt concentrations. From the studies done for asMBL 
at different concentrations of salt, a relation between salt concentration and temperature 
optimum arose; the optimal temperature and the relative activity fell as concentrations of 
salt fell (figure 30). This was the case with VIM-7 also in regards of optimal temperature. As 
asMBL is very resilient to high concentrations of salt, it would be interesting to see if the 
optimal temperature would increase as the salt concentration would increase even further 
than 0.5 M NaCl.  
Other studies have observed the same relation between salt and temperature which has 
been experienced in this study. Niiranen et al observed an upshift in the unfolding 
temperature of their proteins when the salt concentration was increased (Effects of salt on 
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the kinetics and thermodynamic stability of endonuclease I from Vibrio salmonicida and 
Vibrio cholera, Niiranen 2008). However their result indicates an increase of stability of the 
global protein when in relation with increased salt, while the study on asMBL indicates that 
the stability of the active site is increased in relation with increased salt. When combining 
those two results it could mean that a global stabilization of the protein could lead to an 
increased stability of the active site. 
Kinetics 
First and foremost, the credibility of the kinetics results from asMBL has reasons to be 
questioned, when looking at the standard deviation values. It seems to be a rule of thumb 
that the standard deviation should not exceed 10% of the obtained results (119). Both values 
of kcat and Km suffer from high percentage of SD. If the rule of thumb is followed the kcat 
values which can be trusted are those of imipenem, nitrocefin, ertapenem (present in 0.5 M 
NaCl) and cefepime, and the kcat values of meropenem, ertapenem (NaCl not present), 
cefuroxime, ceftadizime and cefoxitin will be more questionable. For the values of Km the 
standard deviation values sometimes are way beyond 10%, the worst example is 
meropenem with a SD of 70%. So if the rule of thumb, with a SD not exceeding 10%, is 
followed strictly, the Km values for hydrolysis of meropenem, ertapenem (with and without 
0.5 M NaCl present), cefuroxime, ceftadizime and cefoxitin are not to be trusted because of 
their wide range. Instead the Km values for hydrolysis of imipenem, nitrocefin and cefepime 
can be trusted. But an SD of 10% is not enforced in all kinetic studies (116, 120). This means 
that some of the results obtained do not necessarily need to be rejected. 
SD is not appropriately used since the variation is not normally distributed (125). Therefore 
many of the SDs that other studies obtain could be questionable as well. But as a better way 
of estimating SD is computer demanding (113) the linear estimation of SD could be used as 
approximately guideline. Having this in mind only general trends will be discussed further. 
The experimental design for measuring Vmax and Km is suggested to be done with substrate 
concentrations in the range of 0.2-5 times the concentration of Km, and equally distributed 
below and above Km (126). Another experimental suggestion in terms of having Km and Vmax 
with as low errors as possible is done with half of the substrate concentrations near Km and 
half of the observations as near Vmax as practical possible, in which no more than 10% of the 
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observations being lower than Km concentration (127). And it is also recommended that the 
spacing of substrate concentrations are geometric sequenced, an example of geometric 
spaced concentrations is as follows; 1 M, 2 M, 4 M, 8 M and so on. In our kinetic 
experiments the most optimal design was geometric spacing of substrate concentrations in 
the range of 0.2-5 times the concentration of Km, in which half of observations were below 
Km and the other half was above Km. 
The general picture is that asMBL is less effective in hydrolyzing the substrates compared to 
the other MBLs which were compared. There is one example with meropenem in which MBL 
perhaps has a better performance constant than one of the other MBL, but this does not 
change the general impression. A reason for this could be the fact that MBL is not in its 
optimal condition during the kinetics experiments, as there is a 40% difference in 
hydrolyzing capability from no NaCl present and 0.5 M NaCl present in the reaction mixture. 
Another reason for asMBL being a less effective MBL could be that the other MBLs which 
were compared are MBLs from clinical samples. MBLs found in hospital have probably 
encountered more antibiotics than asMBL, and have more likely specialized itself more 
towards the synthetic antibiotics found there. For instance, a beta-lactamase found in 
Bacillus subtilis (128), a non-pathogenic organism, shows low beta-lactamase activity. When 
hydrolyzing nitrocefin, the performance constant of beta-lactamase from B. subtilis is 
0,008054 µM-1x s-1, much lower than asMBL performance constant of 1.0 µM-1x s-1. Even 
though the B. subtilis beta-lactamase is not a metallo-beta-lactamases, it could confirm that 
asMBL lack of hydrolyzing properties compared to VIM-2, VIM-7 and IMP-1 is because it has 
not been exposed to antibiotics in the same degree as those MBLs found in organisms 
pathogenic to humans. Some exposure to antibiotics would asMBL possibly encounter as it is 
found in A. salmonicida from a fish farm. This could be the reason for its better hydrolyzing 
capabilities of nitrocefin, compared to beta-lactamases from B. subtilis.  
In regards of kinetics an interesting point is what kind of experimental conditions should the 
kinetic measurements take place in. It is interesting to compare the numbers acquired from 
other studies, as this could reveal new knowledge, for instance about difference in binding 
site between different enzymes and different mutants. But how can it be compared? 
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Well the easy solution is to have the same standard experimental setup for each study; same 
pH, temperature, amount of ions and so on. If substrate and enzyme are affected by the 
conditions they will be affected in the same way. In this study the statement is partially 
correct. 
This study shows that the enzyme is very much affected by the different environment 
surrounding it. Take the kinetic measurement of ertapenem. With 0.5 M NaCl the 
performance constant is rising, indicating a better performance of the enzyme. And to take it 
a step further this value of performance constant is similar to the value which is obtained by 
VIM-7. In this study the performance constants for asMBL is generally lower than for the 
other MBLs. It could be suggested that a better comparison of asMBL against the other MBLs 
would involve optimal conditions for asMBL. When comparing different MBL,s or other 
enzymes for that matter, it would generally be suitable to use the optimal condition for the 
enzyme or the condition in which it is interesting to study it under, for instance in coastal sea 
water or human physiological conditions. 
Nitrocefin reactivity 
Another thing this study has shown is how the substrate is affected by the environment. 
Nitrocefin proved to be unstable when in presence of Tris buffer with high pH. These results 
show how the composition of the reaction mixture can have impact on the behavior of the 
substrate. This could be seen as an argument for having equal experimental conditions when 
comparing properties of enzymes, since then you can rule out those differences that would 
affect the substrate and eventually the final results.  
In this study there was no intention of characterization of nitrocefin's properties. But results 
from characterization of pH optimum and temperature optimum for asMBL gave some 
unexpected and unexplainable results. This was seen especially when measuring pH 
optimum, and to address this problem the different experimental parameters were tested. 
In the end, two experimental properties were observed to influence on the stability of 
nitrocefin; pH and Tris. And the interesting feature is that there seem to be a synergistic 
relationship between Tris and pH and the auto-hydrolysis of nitrocefin. When using Hepes as 
a buffer no apparent auto-hydrolysis of nitrocefin occurs at any pH, while using Tris as a 
buffer auto-hydrolysis occurs at pH 7 and higher (figure 32). This indicates that the buffer, 
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Tris, is important for auto-hydrolysis. When varying concentrations of Tris with pH 7.5, there 
is a relationship between the amount of Tris present and the auto-hydrolysis of nitrocefin, 
but only to a certain degree. There is no linear relationship between the amount of Tris and 
the auto-hydrolysis of nitrocefin, since at about 0.08 M Tris the rate of auto-hydrolysis 
declines. The fact that there is no linear relationship could result from the hypothetic 
synergistic relationship between Tris concentration and pH, but could very well be of some 
other origin. 
Another interesting feature about the relationship between pH and auto-hydrolysis of 
nitrocefin is that at pH 8 a noticeable increase in auto-hydrolysis occurs. This corresponds to 
the pka-value of Tris which is 8.1, and could indicate that the ionic form of Tris is responsible 
for the auto-hydrolysis of nitrocefin (figure 45). Hepes, which was used as reaction buffer 
after the revelation of Tris auto-hydrolyzing effect, has a pKa of 7.5. At higher pH than 7.5 
Hepes molecule will mostly be neutral charged, while at lower pH then 7.5 the charge of the 
Hepes molecule will be mostly negative. So the reason for Tris auto-hydrolyzing behavior 
could be related to its positive charge. Therefore it is advised to be cautious when using 
buffers which could be positively charged in studies involving nitrocefin. 
 
Figure 45 Structures of the buffers Tris and Hepes. 
But why is it interesting to mention nitrocefin stability when the study is about MBL? 
Nitrocefin is widely used as substrate for beta-lactamases, and in that regard it is interesting 
to mention possible pitfalls when using this substrate. If it was not revealed that nitrocefin 
had lack of stability at high temperatures and in pH together with Tris buffer, some of the 
results in this study would then be more questionable. Also this information would hopefully 
assist others working with this substrate, helping them to avoid the same troubles which 
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arose during this study. For instance, making a mastermix of nitrocefin together with Tris 
buffer could be disastrous for the results if the components are mixed in different time 
intervals, which is often the case. 
An example on how big impact the auto-hydrolysis may have in an experiment; A typical 
blank solution with 20 mM Hepes buffer pH 7.5 present have a OD of about 0.1. A blank 
solution of 20 mM Tris buffer at pH 7.5 which have been left for 30 minutes has an OD of 
0.271. The difference in OD is 0.171. As seen on figure 24 the typical area of measured OD is 
in the range of 0.1 to 2, so the auto-hydrolysis of nitrocefin has a noticeable impact.  
There are many examples of studies where nitrocefin is used together with a Tris buffer; 
steady-state kinetic studies using 50 mM Tris at pH 7.4 (77), steady-state kinetic studies 
using MTEN buffer, which consists of 50 mM Mes, 25 mM Tris, 25 mM ethanolamine and 
100 mM NaCl, at pH ranging from 5.25 to 10.0 (129), and hydrolysis of nitrocefin using 50 
mM Tris buffer at pH 8.0 (130). This shows that many studies using nitrocefin uses Tris as 
buffer. The studies are probably not incorrect but their experimental setup can be 
questioned. A study by Wang et al (129) seems to experience the same trouble as this study, 
because reaction rates at pH ≥7.5 were corrected for background hydrolysis. It is highly 
plausible that the reason for their background hydrolysis of the substrate has the same 
reason as what have been found during this study. This shows that a thorough examination 
of the experimental procedures is important in order for a better study design. 
Inhibitory screening 
From the inhibitory screening done in this study none of the tested molecules had any 
effect. Those that showed promising effects are being regarded as chelators, for instance 
dipicolinc acid (116). But a study by Horsfall et al shows that pyridine-2,4-dicarboxylate 
(similar to the picolinic acids in this study) interacts with the enzyme active site of MBL from 
the molecular subgroup B2 (131). Even though asMBL most likely belongs to the molecular 
subgroup B1, it could be plausible that the picolinic acids in this study might as well be 
interacting with the active site of asMBL. The inhibitory screening in this study is not able to 
differentiate between the picolinic acid’s chelating effect and its hypothetical interaction of 
the active site of asMBL. In this regard a crystal structure with asMBL in complex with a 
70 
 
picolinic acid or experiments that could rule out the chelating effects of picolinic acids would 
be needed to verify the inhibitors interaction with the active site. 
PCR 
Results from the PCR experiment show that MBL is present in at least some Aliivibrio species 
originating from an environment which is more or less free of human influence. This could 
indicate that the asMBL does not necessarily need to be driven forward by antibiotic usage 
in fish farms. asMBL would then seem to be an integrated part of the cell’s genome, and 
maybe have other functions than merely protecting the organism from human antibiotic 
usage. As already mentioned in the introduction, it is speculated that beta-lactamases could 
function as a modulator of quorum sensing. This is only speculation, since it may very well be 
a source of natural antibiotic present where the wild Aliivibrio species live. 
Those Aliivibrio species from the Barents Sea that seem to not possess MBL may still have 
MBL present in its genome as their MBL could be connected to a larger gene. But also 
unspecificity present in the PCR method, for instance unspecificty of primers, could lead to 





MBL from the bacterium Aliivibrio salmonicida has been produced, purified and 
characterized.  At high protein concentrations the asMBL seems unstable which could be 
caused by the non-cleavable histidine-tag and/or the buffer components. Many properties of 
the marine asMBL have been discovered through the characterization. It has a high 
tolerance for salt and is also more adapted to cold temperatures compared to the terrestrial, 
mesophilic enzyme VIM-7. asMBL has optimal activity at temperatures, salinity and pH that 
are according to marine environment which indicates that asMBL is fine-tuned in its natural 
habitat. The substrates which MBL preferably hydrolyze are cephalosporins and 
carbapenems, and asMBL seems not to hydrolyze monobactams, which is according to what 
is observed for MBLs VIM-2, VIM-7 and IMP-1. The enzyme efficiency belonging to asMBL 
seems to be lower than that of VIM-2, VIM-7 and IMP-1, but it is strongly indicated that this 
is because of lack of salt in the reaction mixtures. Zinc ions are important for MBL to function 
as an enzyme. The inhibitors that were given for screening seemed to have no inhibitory 
effect, except for some of them which had a chelating effect on Zinc. 
Experimental conditions have great impact on enzyme behavior, and this study shows that 
enzymes from different environments should be analyzed in great detail so no wrong 
conclusions are drawn. When comparing a marine enzyme with a terrestrial homologue their 
respectively environments should be taken into consideration while analyzing the results. 
Characterization of the substrate may be paramount, as the trials with nitrocefin show. 
Nitrocefin was observed to be unstable at high pH together the buffer Tris, which is a 
molecule that with its positive charge is believed to cause auto-hydrolysis of nitrocefin. 





As it seems like the protein is not stable at higher concentrations the first task to attend to 
would be to find a way to stabilize the protein. For instance using a cleavable histidine tag 
instead of the non-cleavable tag, and perhaps try to purify the protein in higher 
concentrations of salt. A purer and more stable protein would better suit a crystallization 
screening and eventually lead to solving asMBLs structure. Screening of inhibitors and 
cocrystallization of inhibitor-enzyme complex would be the next natural step. For instance, it 
would be interesting to cocrystallize the enzyme together with the inhibitor which had been 
cocrystallised by Horsfall et al (131), in order to see if it binds to the active site to confirm or 
reject their findings.  
Other tasks which could be attended to are kinetic studies at 0.5 M NaCl and see if there is 
an expected increase in enzymatic efficiency for all substrates, not just for ertapenem. 
During this study only artificial substrates synthesized by man to be used as antibiotics 
(except nitrocefin) were used in kinetic studies. It would be interesting if the “natural” 
marine substrate of asMBL could be identified and see if it has anything to do with 
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